Abstract | BACKGROUND: METHODS: RESULTS: Clinical evolution was uneventful in all but one patient who had a probable recurrence of pulmonary embolism on day 4. No hemorrhagic complication, no untoward biological event was observed. On days 5, Marder score was unchanged or had decreased. Plasma levels of recombinant hirudin peaked in between 3 and 4 h following the injection. aPTT values paralleled, and were significantly correlated with plasma levels of recombinant hirudin on day 1 as well on day 5 (r = 0.903, r = 0.948 respectively). Fragment 1 + 2, and thrombin antithrombin complexes non-significantly decreased from day 1 to day 5. CONCLUSIONS: Subcutaneous administration of recombinant hirudin ensures prolonged stable plasma levels of recombinant hirudin which results in efficient anticoagulation. A dose-ranging study conducted with subcutaneous recombinant hirudin in comparison to conventional heparin therapy may answer the question as to efficacy.
|
Authors | F Schiele, A Vuillemenot, P Kramarz, Y Kieffer, J Soria, C Soria, A Camez, M C Mirshahi, J P Bassand |
Journal | Thrombosis and haemostasis
(Thromb Haemost)
Vol. 71
Issue 5
Pg. 558-62
(May 1994)
ISSN: 0340-6245 [Print] Germany |
PMID | 8091380
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Hirudins
- Recombinant Proteins
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Blood Coagulation Tests
- Female
- Hirudins
(administration & dosage, adverse effects, pharmacokinetics)
- Humans
- Injections, Subcutaneous
- Male
- Middle Aged
- Pilot Projects
- Recombinant Proteins
(administration & dosage, adverse effects, pharmacokinetics)
- Thrombophlebitis
(drug therapy, metabolism)
|